Galmed announces development of brain penetrating formulation of Aramchol

Galmed (GLMD) announced the breakthrough development of a brain penetrating new formulation of Aramchol. Crossing of the blood-brain barrier, or BBB, is an essential step to achieve effective treatment effects in Parkinson disease and other CNS diseases. The new Aramchol formulation is characterized by sequestration of the Aramchol in lipid nanoparticles which will be administered by subcutaneous injection for delivery across the BBB. This new Aramchol formulation was co-developed by Galmed and Barcode Nanotech, based on Barcode Nanotech’s proprietary platform. Galmed’s medicinal chemistry work converting Aramchol into a brain-penetrant SCD1 inhibitor position Aramchol as a therapeutic asset for synucleinopathies such as Parkinson disease, multiple systems atrophy, dementia and other CNS indications of unmet need.